0000313216-22-000018.txt : 20221024 0000313216-22-000018.hdr.sgml : 20221024 20221024071350 ACCESSION NUMBER: 0000313216-22-000018 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20221024 FILED AS OF DATE: 20221024 DATE AS OF CHANGE: 20221024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KONINKLIJKE PHILIPS NV CENTRAL INDEX KEY: 0000313216 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05146-01 FILM NUMBER: 221324831 BUSINESS ADDRESS: STREET 1: BREITNER CENTER STREET 2: AMSTELPLEIN 2 CITY: AMSTERDAM STATE: P7 ZIP: 1096 BC BUSINESS PHONE: 31 20 59 77777 MAIL ADDRESS: STREET 1: BREITNER CENTER STREET 2: AMSTELPLEIN 2 CITY: AMSTERDAM STATE: P7 ZIP: 1096 BC FORMER COMPANY: FORMER CONFORMED NAME: KONINKLIJKE PHILIPS ELECTRONICS NV DATE OF NAME CHANGE: 19981217 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPS ELECTRONICS N V DATE OF NAME CHANGE: 19930727 FORMER COMPANY: FORMER CONFORMED NAME: PHILIPS NV DATE OF NAME CHANGE: 19910903 6-K 1 phg-20220930.htm Royal Philips - 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

October 24, 2022

KONINKLIJKE PHILIPS N.V.

(Exact name of registrant as specified in its charter)

Royal Philips

(Translation of registrant’s name into English)

The Netherlands

(Jurisdiction of incorporation or organization)

Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission:

M.J. van Ginneken
Koninklijke Philips N.V.
Amstelplein 2
1096 BC Amsterdam – The Netherlands

This report comprises a copy of the following report:

“Philips’ Third Quarter Results 2022”, dated October 24, 2022.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 24th day of October 2022.

KONINKLIJKE PHILIPS N.V.

/s/ M.J. van Ginneken
(Chief Legal Officer)

Judgements and estimates

...

Philips shape

Philips’   Q3   performance   impacted   by   operational   and   supply   challenges; company   is   taking   immediate   actions   to   restore   performance  

Amsterdam, October 24, 2022

Highlights

  • Group sales amounted to EUR 4.3 billion, with a 5% comparable sales decline, in line with the update provided on October 12, 2022
  • Comparable order intake decreased 6% on the back of 47% growth in Q3 2021
  • Income from operations amounted to a loss of EUR 1.5 billion, mainly due to the previously disclosed EUR 1.5 billion non-cash goodwill and R&D impairment, compared to an income of EUR 358 million in Q3 2021
  • Adjusted EBITA of EUR 209 million, or 4.8% of sales, compared to EUR 512 million, or 12.3% of sales, in Q3 2021
  • Immediate restructuring actions initiated, with approximately EUR 300 million charges expected in the coming quarters
  • Operating cash flow was an outflow of EUR 180 million, compared to an inflow of EUR 256 million in Q3 2021
  • Roy Jakobs appointed as President and CEO of Royal Philips per October 15, 2022

Roy Jakobs, CEO of Royal Philips:

“I am honored to have been given the responsibility to lead Philips, a great company with a strong brand, leading product portfolio, strong customer base and talented employees. However, we face multiple challenges and our Q3 2022 performance reflects this. Although Philips’ strategy and solutions resonate with our stakeholders, we have not lived up to their expectations in recent years.

My immediate priority is therefore to improve execution so that we can start rebuilding the trust of patients, consumers and customers, as well as shareholders and our other stakeholders. We will do this by first further strengthening our patient safety and quality management and addressing the various facets of the Philips Respironics recall; second, by urgently improving our supply chain operations so that we can deliver on our strong order book and improve performance; and third, by simplifying our way of working to improve productivity and increase agility. This includes the difficult, but necessary decision to immediately reduce our workforce by around 4,000 roles globally, which we do not take lightly and will implement with respect towards impacted colleagues. These initial actions are needed to start turning the company around in order to realize Philips’ profitable growth potential and create value for all our stakeholders.

While there is a lot to do in a fast-changing environment, our priorities are clear, and I am fully focused, together with our leadership team, on improving execution. I am committed to open and transparent communications with our stakeholders. We will elaborate further on our plans for Philips at our fourth quarter and annual results publication in January 2023.”

Group and business segment performance

Philips’ performance in the quarter was impacted by operational and supply challenges, inflationary pressures, the COVID situation in China and the Russia-Ukraine war, resulting in Group sales of EUR 4.3 billion, reflecting a 5% comparable sales decline, and an Adjusted EBITA of EUR 209 million, or 4.8% of sales. Operating cash flow was an outflow of EUR 180 million, mainly due to lower cash earnings, increased inventories and higher consumption of provisions. Comparable order intake declined 6% on the back of strong 47% growth in Q3 2021. The book-to-bill ratio was 1.18, and the equipment order book grew further in the quarter.

The Diagnosis & Treatment businesses’ comparable sales decreased 2% on the back of 10% growth in Q3 2021. Comparable order intake increased 3% on the back of 15% growth in Q3 2021. The Adjusted EBITA margin was 9.1%, mainly due to the decline in sales and cost inflation.

The Connected Care businesses’ comparable sales decreased 15%, mainly due to operational and supply challenges. Comparable order intake showed a 24% decrease, on the back of over 260% comparable order intake growth in Q3 2021. The Adjusted EBITA margin amounted to -9.5%, mainly due to the decline in sales and cost inflation.

The Personal Health businesses’ comparable sales increased by 4%, with good growth in North America and Western Europe. The Adjusted EBITA margin amounted to 14.1%.

Highlights of Philips’ ongoing focus on innovation and customer partnerships in the quarter:

  • Demonstrating the trust hospital leaders have in Philips’ ability to help them enhance health outcomes, lower the cost of care and improve patient and staff experience, the company signed multiple new long-term strategic partnerships across the world. This included a 10-year agreement with a large university hospital in Japan for the expansion of its eICU program for centralized, remote surveillance of high-risk ICU patients.
  • Philips signed several agreements in China, including with private hospitals Suzhou Kowloon Hospital and Wuhan Asia Heart Hospital to provide advanced diagnostic imaging and image-guided therapy systems to advance patient care.
  • Philips expanded its leading ultrasound portfolio with the FDA market clearance for its new Ultrasound 5000 Compact system to deliver cart-based premium image quality in compact form for point-of-care, cardiology, general imaging, and obstetrics and gynecology applications.
  • Philips continues to successfully expand into ambulatory care. Newly published research validated that Philips Mobile Cardiac Outpatient Telemetry (MCOT) is crucial in detecting arrhythmias and providing data that allows care teams to intervene quickly and decisively to provide the optimal patient treatment.
  • Building on its successful OneBlade platform, Philips introduced in Europe the new OneBlade 360, which leverages a new blade that adjusts to the curves of the face to enhance shaving comfort.

Philips Respironics field action for specific sleep therapy and ventilator devices

Philips Respironics continued to make progress with the repair and replacement program and the comprehensive test and research program for the CPAP, BiPAP and mechanical ventilator devices affected by the June 2021 field safety notice. To date, approximately 4 million replacement devices and repair kits have been produced. Philips Respironics aims to complete around 90% of the production and shipments to customers in 2022. 

As previously communicated, following the FDA’s inspection of certain of Philips Respironics’ facilities in the US in 2021 and the subsequent inspectional observations, the US Department of Justice, acting on behalf of the FDA, began discussions with Philips in July 2022 regarding the terms of a proposed consent decree to resolve the identified issues.

Due to revisions to the financial forecast of Philips Respironics driven by current assumptions regarding the estimated impact of the proposed consent decree and changes to the pre-tax discount rate, Philips is recording a EUR 1.3 billion non-cash charge in the third quarter for the impairment of goodwill of this business.

As disclosed, Philips Respironics is subject to an investigation by the US Department of Justice, is a defendant in several class-action lawsuits and individual personal injury claims, and is in ongoing discussions with the FDA regarding the proposed consent decree. Given the uncertain nature and timing of the relevant events, and of their potential financial and operational impact and associated obligations, if any, the company has not made any provisions in the accounts for these matters.

Productivity initiatives and other actions to improve performance  

Philips has initiated general productivity actions, including simplifying the organization to streamline the way of working and reduce operating expenses. This includes an immediate reduction of around 4,000 positions globally across the organization, subject to consultation with the relevant workers councils and social partners, with severance and termination-related costs expected to be approximately EUR 300 million in the coming quarters. The associated cost savings are expected to amount to annualized savings of approximately EUR 300 million. Philips will continue to review areas to further improve its supply operations, invest in quality, simplify the way of working and remove organizational complexity, which is expected to result in additional restructuring and associated costs in 2023.

Additionally, Philips is urgently implementing several actions to enhance performance and productivity in the supply chain (e.g. dual sourcing, supplier consolidation, warehouse footprint rationalization), R&D (e.g. shifting the focus to fewer, high-impact projects in the innovation pipeline) and quality (e.g. enhancing processes, increasing capabilities and product management). In connection with the previously announced initiative to enhance productivity in R&D, Philips recorded a non-cash charge in the third quarter of EUR 168 million.

Outlook

Looking ahead, the company sees prolonged operational and supply challenges, a worsening macro-economic environment and continued uncertainty related to COVID-19 measures in China, which will be partly offset by Philips’ productivity and pricing actions. Consequently, Philips now expects a mid-single-digit comparable sales decline for the fourth quarter of 2022, with a high-single-to-double-digit Adjusted EBITA margin range.

Capital allocation

In light of recent developments and market volatility, Philips is taking the following measures – in addition to its measures to manage cash – to further strengthen its liquidity position:

  • Securing a EUR 1 billion credit facility. 
  • Executing the settlement of the forward contracts – entered into as part of the share repurchase program announced on July 26, 2021 – at the original settlement dates in 2023 and 2024, instead of in 2022 as earlier announced.

Conference call and audio webcast

Roy Jakobs, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.

Philips performance

Key data

in millions of EUR unless otherwise stated

  Q3 2021 Q3 2022
Sales 4,156 4,310
Nominal sales growth (6)% 4%
Comparable sales growth1) (8)% (5)%
Comparable order intake2) 47% (6)%
Income from operations 358 (1,529)
as a % of sales 8.6% (35.5)%
Financial income and expenses, net (5) (46)
Investments in associates, net of income taxes (3) 91
Income tax (expense) benefit 92 156
Income from continuing operations 442 (1,330)
Discontinued operations, net of income taxes 2,538 1
Net income 2,980 (1,329)
Earnings per common share (EPS)    
Income from continuing operations attributable to shareholders3) (in EUR) - diluted 0.47 (1.50)
Adjusted income from continuing operations attributable to shareholders3) (in EUR) - diluted1) 0.40 0.25
Net income attributable to shareholders3) per common share (in EUR) - diluted 3.24 (1.50)
EBITA1) 426 (94)
as a % of sales 10.2% (2.2)%
Adjusted EBITA1) 512 209
as a % of sales 12.3% 4.8%
Adjusted EBITDA1) 739 466
as a % of sales 17.8% 10.8%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. 2) Comparable order intake is presented when discussing the Philips Group’s performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. 3) Shareholders refers to shareholders of Koninklijke Philips N.V. 
  • Comparable sales declined by 5%, mainly due to operational and supply chain challenges, the COVID situation in China and the Russia-Ukraine war. Comparable sales in the Personal Health businesses showed mid-single-digit growth, while the Connected Care and Diagnosis & Treatment businesses recorded a double-digit and low-single-digit decline respectively.
  • Comparable order intake decreased by 6% on the back of 47% growth in Q3 2021, with low-single-digit growth in the Diagnosis & Treatment businesses, which was more than offset by a double-digit decline in the Connected Care businesses. 
  • Adjusted EBITA was EUR 209 million and the margin amounted to 4.8%, due to the decline in sales and cost inflation, partly offset by productivity and pricing measures.
  • Income from operations includes a charge of EUR 1.5 billion related to a goodwill and R&D impairment.
  • Restructuring, acquisition-related and other charges amounted to EUR 303 million, compared to EUR 87 million in Q3 2021. Q3 2022 includes an impairment of EUR 134 million related to the discontinuation of certain R&D projects. Restructuring and acquisition-related charges amounted to EUR 47 million. This further includes Respironics field-action running remediation costs of EUR 47 million, provisions for earlier announced quality actions in Connected Care of EUR 34 million, and a charge related to the impairment of assets within the Sleep & Respiratory Care business of EUR 30 million.
  • Financial income and expenses resulted in an expense of EUR 46 million, compared to an expense of EUR 5 million in Q3 2021. Q3 2022 includes higher interest expense, primarily due to bonds issued in April 2022 and lower interest income compared to Q3 2021.
  • Investments in associates mainly includes a gain from the sale of an investment in associates.
  • Income tax expense decreased by EUR 64 million year-on-year. The tax benefit in Q3 2022 is due to a loss position partly offset by a non-tax-deductible impairment. The tax benefit in Q3 2021 was due to a one-off benefit relating to the recognition of tax assets as a result of a business transfer, more than offsetting the tax expense on income.
  • Net income in Q3 2022 amounted to a loss of EUR 1.3 billion, mainly due to a charge of EUR 1.3 billion related to an impairment of goodwill in the Sleep & Respiratory Care business. Net income in Q3 2021 amounted to a profit of EUR 3.0 billion, mainly related to the result on the sale of the Domestic Appliances business.

Sales per geographic cluster

in millions of EUR unless otherwise stated

      % change
  Q3 2021 Q3 2022 nominal comparable1)
Western Europe 870 856 (2)% (5)%
North America 1,670 1,799 8% (7)%
Other mature geographies 383 373 (3)% 0%
Total mature geographies 2,924 3,028 4% (6)%
Growth geographies 1,231 1,282 4% (4)%
Philips Group 4,156 4,310 4% (5)%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

Amounts may not add up due to rounding

  • Comparable sales declined by 5%, mainly due to operational and supply chain challenges, the COVID situation in China and the Russia-Ukraine war. Sales in mature geographies decreased by 6%, due to a high-single-digit decline in North America and a mid-single-digit decline in Western Europe. In growth geographies, sales decreased by 4% on a comparable basis, mainly due to Russia & Central Asia.

Cash and cash equivalents balance

in millions of EUR

  Q3 2021 Q3 2022
Beginning cash balance 1,019 1,258
Free cash flow1) 45 (374)
Net cash flows from operating activities 256 (180)
Net capital expenditures (210) (195)
Other cash flows from investing activities (40) (203)
Treasury share transactions (84) -
Changes in debt (909) 118
Withholding tax paid on dividend (73) (62)
Other cash flow items 8 21
Net cash flows from discontinued operations 3,860 18
Ending cash balance 3,827 776
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Net cash flows from operating activities decreased, mainly due to lower cash earnings and cash costs related to the Philips Respironics field action.
  • Other cash flows from investing activities mainly includes new participations in investments in associates.
  • Treasury shares transactions in Q3 2021 included share repurchases for capital reduction purposes and employee stock purchase plans.
  • Changes in debt includes the issuance of commercial paper of EUR 200 million, partly offset by debt repayments. Q3 2021 included repayments of commercial paper amounting to EUR 300 million and two bilateral loans totaling EUR 500 million.
  • Net cash flows from discontinued operations in Q3 2021 included the net cash proceeds received on the sale of the Domestic Appliances business.

Composition of net debt to group equity1)

in millions of EUR unless otherwise stated

  June 30, 2022 September 30, 2022
Long-term debt 6,788 6,910
Short-term debt 1,213 1,397
Total debt 8,001 8,307
Cash and cash equivalents 1,258 776
Net debt 6,743 7,531
Shareholders' equity 14,727 14,437
Non-controlling interests 39 43
Group equity 14,766 14,479
Net debt : group equity ratio1) 31:69 34:66
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Philips will execute the settlement of the forward contracts – entered into as part of the share repurchase program announced on July 26, 2021 – at the original settlement dates in 2023 and 2024, instead of in 2022 as earlier announced. As a result, EUR 416 million of short-term debt presented here will be reclassified to long-term debt during the fourth quarter.

Performance per segment

Diagnosis & Treatment businesses

Key data

in millions of EUR unless otherwise stated

  Q3 2021 Q3 2022
Sales 2,154 2,292
Sales growth    
Nominal sales growth 9% 6%
Comparable sales growth1) 10% (2)%
Income from operations 271 46
as a % of sales 12.6% 2.0%
EBITA1) 295 84
as a % of sales 13.7% 3.7%
Adjusted EBITA1) 306 209
as a % of sales 14.2% 9.1%
Adjusted EBITDA1) 373 277
as a % of sales 17.3% 12.1%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales declined by 2% in Q3 2022, with low-single-digit growth in Image-Guided Therapy, which was more than offset by a decline in Ultrasound and in Diagnostic Imaging due to specific electronic component shortages.
  • Comparable sales in mature geographies showed a mid-single-digit decline on the back of double-digit growth in Q3 2021. Growth geographies were in line with Q3 2021.
  • Adjusted EBITA was EUR 209 million and the margin amounted to 9.1%, mainly due to the decline in sales and cost inflation.  
  • Restructuring, acquisition-related and other charges amounted to EUR 125 million, compared to EUR 12 million in Q3 2021. Q3 2022 includes an impairment of EUR 120 million related to the discontinuation of certain R&D projects. In Q4 2022, restructuring, acquisition-related and other charges are expected to total approximately EUR 60 million.

Connected Care businesses

Key data

in millions of EUR unless otherwise stated

  Q3 2021 Q3 2022
Sales 1,040 982
Sales growth    
Nominal sales growth (33)% (6)%
Comparable sales growth1) (39)% (15)%
Income from operations (32) (1,640)
as a % of sales (3.1)% (167.0)%
EBITA1) 5 (249)
as a % of sales 0.5% (25.4)%
Adjusted EBITA1) 67 (93)
as a % of sales 6.4% (9.5)%
Adjusted EBITDA1) 114 (25)
as a % of sales 11.0% (2.5)%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales declined by 15%, mainly due to the impact of operational and supply chain challenges.
  • Comparable sales in mature geographies and growth geographies showed a double-digit decline. 
  • Adjusted EBITA was EUR (93) million and the margin amounted to (9.5%), mainly due to the decline in sales and cost inflation.
  • Income from operations includes a charge of EUR 1.3 billion related to an impairment of goodwill. 
  • Restructuring, acquisition-related and other charges were EUR 155 million, compared to EUR 62 million in Q3 2021. Q3 2022 includes Respironics field-action running remediation costs of EUR 47 million, provisions for earlier announced quality actions in Connected Care of EUR 34 million, a charge related to the impairment of assets within the Sleep & Respiratory Care business of EUR 30 million, and acquisition-related costs of EUR 22 million. In Q4 2022, restructuring, acquisition-related and other charges are expected to total approximately EUR 135 million. 

Personal Health businesses

Key data

in millions of EUR unless otherwise stated

  Q3 2021 Q3 2022
Sales 808 902
Sales growth    
Nominal sales growth 0% 12%
Comparable sales growth1) 0% 4%
Income from operations 122 120
as a % of sales 15.1% 13.3%
EBITA1) 125 124
as a % of sales 15.5% 13.7%
Adjusted EBITA1) 126 127
as a % of sales 15.6% 14.1%
Adjusted EBITDA1) 155 155
as a % of sales 19.2% 17.2%
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Comparable sales growth was 4%, with high-single-digit growth in Oral Healthcare and in Mother & Child Care and low-single-digit growth in Personal Care. 
  • Comparable sales in mature geographies showed double-digit growth, driven by double-digit growth in Western Europe and high-single-digit growth in North America. Growth geographies recorded a low-single-digit decline, due to a double-digit decline in Russia & Central Asia, partly offset by double-digit growth in Middle East & Turkey and low-single-digit growth in China.
  • Adjusted EBITA was EUR 127 million and the margin amounted to 14.1%, mainly due to cost inflation and an adverse currency impact, partly offset by the increase in sales, productivity measures and a favorable price impact. 
  • In Q4 2022, restructuring, acquisition-related and other charges are expected to total approximately EUR 5 million. 

Other

Key data

in millions of EUR

  Q3 2021 Q3 2022
Sales 153 135
Income from operations (2) (55)
EBITA1) 0 (54)
Adjusted EBITA1) of: 13 (34)
IP Royalties 101 53
Innovation (41) (28)
Central costs (53) (54)
Other 5 (5)
Adjusted EBITDA1) 97 59
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.
  • Sales decreased by EUR 18 million, mainly due to phasing of royalty income, partly offset by an increase in supplies to the divested Domestic Appliances business.
  • Adjusted EBITA decreased by EUR 47 million, mainly due to phasing of royalty income and an adverse currency impact, partly offset by cost savings.
  • Restructuring, acquisition-related and other charges amounted to EUR 21 million, compared to EUR 12 million in Q3 2021. Q3 2022 includes restructuring costs of EUR 14 million and costs related to the re-measurement of environmental liabilities of EUR 9 million. In Q4 2022, restructuring and other charges are expected to total approximately EUR 30 million. 

Forward-looking statements and other important information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*), future restructuring and acquisition-related charges and other costs, future developments in Philips’ organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “should”, “will”, “will likely result”, “forecast”, “outlook”, “projects”, “may” or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include but are not limited to: Philips’ ability to gain leadership in health informatics in response to developments in the health technology industry; Philips’ ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips’ intellectual property rights, and unauthorized use of third-party intellectual property rights; Philips’ ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breaches of cybersecurity; Philips’ ability to execute and deliver on programs on business transformation and IT system changes and continuity; the effectiveness of our supply chain; attracting and retaining personnel; COVID and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security; compliance with business conduct rules and regulations; treasury and financing risks; tax risks; reliability of internal controls, financial reporting and management process. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2021. Reference is also made to Risk management in the Philips semi-annual report 2022.

Philips has recognized a provision related to the voluntary recall notification in the US/field safety notice outside the US for certain sleep and respiratory care products, based on Philips’ best estimate for the expected field actions. Future developments are subject to significant uncertainties, which require management to make estimates and assumptions about items such as quantities and the portion to be replaced or repaired. Actual outcomes in future periods may differ from these estimates and affect the company's results of operations, financial position and cash flows.

During the quarter, an indicator of impairment was identified for the Sleep & Respiratory Care cash-generating unit (CGU) as a consequence of revisions to the expected future cash flows of the CGU. The goodwill impairment charge recognized this quarter is due to revisions to the financial forecast of our Sleep & Respiratory Care business within the Connected Care segment. The impairment charge was calculated by comparing the carrying amount of the Sleep & Respiratory Care CGU with its recoverable amount, the basis of which is value in use. The forecast used to calculate the value in use required management to make significant estimates and assumptions about future cash flows. Actual outcomes in future periods may differ from these estimates. After this impairment charge, the estimated recoverable amount for Sleep & Respiratory Care is equal to its carrying value and consequently any adverse change in key assumptions would individually cause a material impairment loss to be recognized.

Third-party market share data

Statements regarding market share, contained in this document, including those regarding Philips’ competitive position, are based on outside sources such as specialized research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management’s estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2021.

Use of fair value information

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2021. In certain cases independent valuations are obtained to support management’s determination of fair values.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to the totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2021 except for the adoption of new standards and amendments to standards which are also expected to be reflected in the company’s consolidated financial statements for the year ending December 31, 2022.

Prior-period amounts have been reclassified to conform to the current-period presentation; this includes immaterial organizational changes.

*) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

Condensed consolidated statements of income

In millions of EUR unless otherwise stated

  Q3 January to September
  2021 2022 2021 2022
Sales 4,156 4,310 12,212 12,405
Cost of sales (2,182) (2,580) (6,963) (7,432)
Gross margin 1,973 1,730 5,250 4,973
Selling expenses (1,041) (1,154) (3,083) (3,329)
General and administrative expenses (164) (175) (475) (476)
Research and development expenses (437) (615) (1,331) (1,600)
     Impairment of goodwill (1,331) (15) (1,331)
Other business income 31 19 141 101
Other business expenses (4) (4) (95) (39)
Income from operations 358 (1,529) 391 (1,700)
Financial income 38 23 114 60
Financial expenses (43) (69) (132) (182)
Investment in associates, net of income taxes (3) 91 4 84
Income before taxes 350 (1,485) 376 (1,738)
Income tax (expense) benefit 92 156 97 233
Income from continuing operations 442 (1,330) 473 (1,505)
Discontinued operations, net of income taxes 2,538 1 2,699 5
Net income 2,980 (1,329) 3,173 (1,500)
Attribution of net income        
Income from continuing operations attributable to shareholders of Koninklijke Philips N.V. 435 (1,331) 463 (1,508)
Net income attributable to shareholders1) 2,973 (1,330) 3,162 (1,503)
Net income attributable to non-controlling interests 7 1 10 3
Earnings per common share        
Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands):        
- basic 912,555 885,332 908,416 879,094
- diluted 916,981 885,332 914,219 879,094
Income from continuing operations attributable to shareholders1)        
- basic 0.48 (1.50) 0.51 (1.72)
- diluted 0.47 (1.50) 0.51 (1.72)
Net income attributable to shareholders1)        
- basic 3.26 (1.50) 3.48 (1.71)
- diluted 3.24 (1.50) 3.46 (1.71)
1) Shareholders refers to shareholders of Koninklijke Philips N.V. 

Amounts may not add up due to rounding

Reconciliation of non-IFRS information

Certain non-IFRS financial measures are presented when discussing the Philips Group’s performance:

  • Comparable sales growth
  • EBITA
  • Adjusted EBITA
  • Adjusted income from continuing operations attributable to shareholders
  • Adjusted income from continuing operations attributable to shareholders per common share (in EUR) - diluted (Adjusted EPS)
  • Adjusted EBITDA
  • Free cash flow
  • Net debt : group equity ratio

For the definitions of the non-IFRS financial measures listed above, refer to chapter 12, Reconciliation of non-IFRS information, of the Annual Report 2021 and to the Forward-looking statements and other important information.

Sales growth composition

in %

  Q3 2022 January to September
  nominal growth consolidation changes currency effects comparable growth nominal growth consolidation changes currency effects comparable growth
2022 versus 2021                
Diagnosis & Treatment 6.4% 0.0% (8.8)% (2.4)% 3.8% 0.0% (6.8)% (3.0)%
Connected Care (5.6)% (0.7)% (8.3)% (14.6)% (10.1)% 0.0% (6.3)% (16.4)%
Personal Health 11.6% 0.0% (7.2)% 4.4% 8.1% 0.0% (6.0)% 2.0%
Philips Group 3.7% (0.7)% (8.1)% (5.1)% 1.6% (0.4)% (6.4)% (5.2)%

Adjusted income from continuing operations attributable to shareholders1)

in millions of EUR unless otherwise stated

  Q3 January to September
  2021 2022 2021 2022
Net income 2,980 (1,329) 3,173 (1,500)
Discontinued operations, net of income taxes (2,538) (1) (2,699) (5)
Income from continuing operations 442 (1,330) 473 (1,505)
Continuing operations non-controlling interests (7) (1) (10) (3)
Income from continuing operations attributable to shareholders 1) 435 (1,331) 463 (1,508)
Adjustments for:        
Amortization and impairment of acquired intangible assets 67 105 253 260
Impairment of goodwill 1,331 15 1,331
Restructuring and acquisition-related charges 15 47 68 85
Other items: 72 256 678 692
        Respironics field-action provision 500 165
        Respironics field-action running remediation costs 43 47 47 147
        Impairment of assets in S&RC   30   30
        Provisions for quality actions in Connected Care   34   66
        Portfolio realignment charges 11 54 109
        R&D project impairments   134   134
        Loss on divestment of business 70
        Remaining items 17 10 7 39
Net finance expenses (14) (7) (63) (4)
Tax impact of adjusted items and tax only adjusting items (210) (180) (424) (369)
Adjusted income from continuing operations attributable to shareholders 1) 365 220 991 486
Earnings per common share:        
Income from continuing operations attributable to shareholders1) per common share (in EUR) - diluted 0.47 (1.50) 0.51 (1.72)
Adjusted income from continuing operations attributable to shareholders1) per common share (EUR) - diluted 0.40 0.25 1.08 0.55
1) Shareholders refers to shareholders of Koninklijke Philips N.V. 

Reconciliation of Net income to Adjusted EBITA

in millions of EUR

  Philips Group Diagnosis & Treatment Connected Care Personal Health Other
Q3 2022          
Net income (1,329)        
Discontinued operations, net of income taxes (1)        
Income tax benefit (156)        
Investments in associates, net of income taxes (91)        
Financial expenses 69        
Financial income (23)        
Income from operations (1,529) 46 (1,640) 120 (55)
Amortization and impairment of acquired intangible assets  105 39 61 4 1
Impairment of goodwill 1,331 1,331
EBITA (94) 84 (249) 124 (54)
Restructuring and acquisition-related charges 47 5 28 - 14
Other items: 256 120 127 3 7
        Respironics field-action running remediation costs 47 47
        Impairment of assets in S&RC 30   30    
        Provisions for quality actions in Connected Care 34 34
        R&D project impairments 134 120 12 3
        Remaining items 10 - 4 7
Adjusted EBITA 209 209 (93) 127 (34)
           
January to September 2022          
Net income (1,500)        
Discontinued operations, net of income taxes (5)        
Income tax benefit (233)        
Investments in associates, net of income taxes (84)        
Financial expenses 182        
Financial income (60)        
Income from operations (1,700) 246 (2,168) 343 (120)
Amortization and impairment of acquired intangible assets 260 94 150 12 4
Impairment of goodwill 1,331 1,331
EBITA (109) 340 (687) 354 (116)
Restructuring and acquisition-related charges 85 (4) 65 1 23
Other items: 692 120 545 3 24
        Respironics field-action provision 165 165
        Respironics field-action running remediation costs 147 147
        Impairment of assets in S&RC 30   30    
        Provisions for quality actions in Connected Care 66 66
        Portfolio realignment charges 109 109
        R&D project impairments 134 120 12 3
        Remaining items 39 15 24
Adjusted EBITA 667 456 (77) 358 (69)
Q3 2021          
Net income 2,980        
Discontinued operations, net of income taxes (2,538)        
Income tax benefit (92)        
Investments in associates, net of income taxes 3        
Financial expenses 43        
Financial income (38)        
Income from operations 358 271 (32) 122 (2)
Amortization and impairment of acquired intangible assets 67 23 38 4 3
Impairment of goodwill
EBITA 426 295 5 125 -
Restructuring and acquisition-related charges 15 8 8 - (2)
Other items: 72 4 54 - 14
        Respironics field-action running remediation costs 43 44 (1)
        Portfolio realignment charges       11 11  
        Remaining items 17 4 (1) - 15
Adjusted EBITA 512 306 67 126 13
           
January to September 2021          
Net income 3,173        
Discontinued operations, net of income taxes (2,699)        
Income tax benefit (97)        
Investments in associates, net of income taxes (4)        
Financial expenses 132        
Financial income (114)        
Income from operations 391 627 (408) 356 (183)
Amortization and impairment of acquired intangible assets 253 128 109 11 5
Impairment of goodwill 15 2 13
EBITA 660 757 (286) 367 (178)
Restructuring and acquisition-related charges 68 22 46 - (1)
Other items: 678 (32) 592 - 119
        Respironics field-action provision       500   500    
        Respironics field-action running remediation costs 47   47    
        Portfolio realignment charges 54   54    
        Loss on divestment of business 70       70
        Remaining items 7 (32) (10) - 49
Adjusted EBITA 1,406 747 352 368 (60)

Reconciliation of Net income to Adjusted EBITDA

in millions of EUR

  Philips Group Diagnosis & Treatment Connected Care Personal Health Other
Q3 2022          
Net income (1,329)        
Discontinued operations, net of income taxes (1)        
Income tax benefit (156)        
Investments in associates, net of income taxes (91)        
Financial expenses 69        
Financial income (23)        
Income from operations (1,529) 46 (1,640) 120 (55)
Depreciation, amortization and impairments of fixed assets 525 229 168 34 94
Impairment of goodwill 1,331 1,331
Restructuring and acquisition-related charges 47 5 28 - 14
Other items: 256 120 127 3 7
        Respironics field-action running remediation costs 47 47
        Impairment of assets in S&RC 30   30    
        Provisions for quality actions in Connected Care 34 34
        R&D project impairments 134 120 12 3
        Remaining items 10 - 4 7
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (163) (122) (39) (3) -
Adjusted EBITDA 466 277 (25) 155 59
           
January to September 2022          
Net income (1,500)        
Discontinued operations, net of income taxes (5)        
Income tax benefit (233)        
Investments in associates, net of income taxes (84)        
Financial expenses 182        
Financial income (60)        
Income from operations (1,700) 246 (2,168) 343 (120)
Depreciation, amortization and impairments of fixed assets 1,222 434 407 100 281
Impairment of goodwill 1,331 1,331
Restructuring and acquisition-related charges 85 (4) 65 1 23
Other items: 692 120 545 3 24
        Respironics field-action provision       165 165
        Respironics field-action running remediation costs 147 147
        Impairment of assets in S&RC 30   30    
        Provisions for quality actions in Connected Care 66 66
        Portfolio realignment charges       109 109
        R&D project impairments 134 120 12 3  
        Remaining items 39   15 24
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (215) (135) (71) (3) (6)
Adjusted EBITDA 1,414 660 108 444 202
Q3 2021          
Net income 2,980        
Discontinued operations, net of income taxes (2,538)        
Income tax benefit (92)        
Investments in associates, net of income taxes 3        
Financial expenses 43        
Financial income (38)        
Income from operations 358 271 (32) 122 (2)
Depreciation, amortization and impairments of fixed assets 309 92 98 33 87
Impairment of goodwill
Restructuring and acquisition-related charges 15 8 8 - (2)
Other items: 72 4 54 - 14
        Respironics field-action running remediation costs 43   44   (1)
        Portfolio realignment charges 11   11    
        Remaining items 17 4 (1) 15
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (15) (2) (13) -
Adjusted EBITDA 739 373 114 155 97
           
January to September 2021          
Net income 3,173        
Discontinued operations, net of income taxes (2,699)        
Income tax benefit (97)        
Investments in associates, net of income taxes (4)        
Financial expenses 132        
Financial income (114)        
Income from operations 391 627 (408) 356 (183)
Depreciation, amortization and impairments of fixed assets 980 351 273 96 260
Impairment of goodwill 15 2 13
Restructuring and acquisition-related charges 68 22 46 - (1)
Other items: 678 (32) 592 - 119
        Respironics field-action provision       500   500    
        Respironics field-action running remediation costs  47   47    
        Portfolio realignment charges 54   54    
        Loss on divestment of business 70       70
        Remaining items 7 (32) (10)   49
Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items (53) (19) (35) 2
Adjusted EBITDA 2,080 951 480 453 196

Composition of free cash flow

in millions of EUR

  Q3
  2021 2022
Net cash flows from operating activities 256 (180)
Net capital expenditures (210) (195)
Purchase of intangible assets (36) (38)
Expenditures on development assets (60) (68)
Capital expenditures on property, plant and equipment (112) (90)
Proceeds from disposals of property, plant and equipment (1) 1
Free cash flow 45 (374)

Philips statistics

In millions of EUR unless otherwise stated

  2021 2022
  Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Sales 3,827 4,230 4,156 4,944 3,918 4,177 4,310  
Comparable sales growth1) 9% 9% (8)% (10)% (4)% (7)% (5)%  
Comparable order intake2) (5)% (15)% 47% 4% 5% 1% (6)%  
Gross margin 1,487 1,789 1,973 1,918 1,511 1,731 1,730  
as a % of sales 38.9% 42.3% 47.5% 38.8% 38.6% 41.4% 40.1%  
Selling expenses (986) (1,056) (1,041) (1,175) (1,064) (1,111) (1,154)  
as a % of sales (25.8)% (25.0)% (25.0)% (23.8)% (27.2)% (26.6)% (26.8)%  
G&A expenses (173) (138) (164) (124) (155) (146) (175)  
as a % of sales (4.5)% (3.3)% (3.9)% (2.5)% (4.0)% (3.5)% (4.1)%  
R&D expenses (424) (470) (437) (475) (495) (490) (615)  
as a % of sales (11.1)% (11.1)% (10.5)% (9.6)% (12.6)% (11.7)% (14.3)%  
Income from operations (52) 85 358 162 (181) 11 (1,529)  
as a % of sales (1.4)% 2.0% 8.6% 3.3% (4.6)% 0.3% (35.5)%  
Net income 40 153 2,980 151 (151) (20) (1,329)  
Income from continuing operations attributable to shareholders3) per common share in EUR - diluted (0.04) 0.07 0.47 0.16 (0.17) (0.03) (1.50)  
Adjusted income from continuing operations attributable to shareholders3) per common share in EUR - diluted1) 0.28 0.40 0.40 0.57 0.15 0.14 0.25  
EBITA1) 61 173 426 230 (107) 92 (94)  
as a % of sales 1.6% 4.1% 10.2% 4.6% (2.7)% 2.2% (2.2)%  
Adjusted EBITA1) 362 532 512 647 243 216 209  
as a % of sales 9.5% 12.6% 12.3% 13.1% 6.2% 5.2% 4.8%  
Adjusted EBITDA1) 579 762 739 905 488 461 466  
as a % of sales 15.1% 18.0% 17.8% 18.3% 12.5% 11.0% 10.8%  
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. 2) Comparable order intake is presented when discussing the Philips Group’s performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. 3) Shareholders refers to shareholders of Koninklijke Philips N.V. 

Philips statistics in millions of EUR unless otherwise stated

  2021 2022
  January-March January-June January-September January-December January-March January-June January-September January-December
Sales 3,827 8,057 12,212 17,156 3,918 8,095 12,405  
Comparable sales growth1) 9% 9% 3% (1)% (4)% (5)% (5)%  
Comparable order intake2) (5)% (11)% 4% 4% 5% 3% (1)%  
Gross margin 1,487 3,277 5,250 7,168 1,511 3,243 4,973  
as a % of sales 38.9% 40.7% 43.0% 41.8% 38.6% 40.1% 40.1%  
Selling expenses (986) (2,042) (3,083) (4,258) (1,064) (2,175) (3,329)  
as a % of sales (25.8)% (25.3)% (25.2)% (24.8)% (27.2)% (26.9)% (26.8)%  
G&A expenses (173) (311) (475) (599) (155) (301) (476)  
as a % of sales (4.5)% (3.9)% (3.9)% (3.5)% (4.0)% (3.7)% (3.8)%  
R&D expenses (424) (894) (1,331) (1,806) (495) (985) (1,600)  
as a % of sales (11.1)% (11.1)% (10.9)% (10.5)% (12.6)% (12.2)% (12.9)%  
Income from operations (52) 33 391 553 (181) (170) (1,700)  
as a % of sales (1.4)% 0.4% 3.2% 3.2% (4.6)% (2.1)% (13.7)%  
Net income 40 192 3,173 3,323 (151) (171) (1,500)  
Income from continuing operations attributable to shareholders3) per common share in EUR - diluted (0.04) 0.03 0.51 0.67 (0.17) (0.20) (1.72)  
Adjusted income from continuing operations attributable to shareholders3) per common share in EUR - diluted1) 0.28 0.69 1.08 1.65 0.15 0.30 0.55  
EBITA1) 61 234 660 890 (107) (15) (109)  
as a % of sales 1.6% 2.9% 5.4% 5.2% (2.7)% (0.2)% (0.9)%  
Adjusted EBITA1) 362 894 1,406 2,054 243 459 667  
as a % of sales 9.5% 11.1% 11.5% 12.0% 6.2% 5.7% 5.4%  
Adjusted EBITDA1) 579 1,341 2,080 2,985 488 948 1,414  
as a % of sales 15.1% 16.6% 17.0% 17.4% 12.5% 11.7% 11.4%  
Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) 905,289 912,734 910,306 870,182 869,298 885,316 885,348  
Shareholders' equity per common share in EUR 13.80 13.10 16.00 16.59 16.64 16.63 16.31  
Net debt : group equity ratio1) 34:66 36:64 21:79 24:76 28:72 31:69 34:66  
Total employees 77,343 77,084 77,746 78,189 78,548 78,831 79,097  
1) Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. 2) Comparable order intake is presented when discussing the Philips Group’s performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. 3) Shareholders refers to shareholders of Koninklijke Philips N.V. 

© 2022 Koninklijke Philips N.V.

All rights reserved.

https://www.philips.com/investorrelations
Philips shield
GRAPHIC 2 visual0001.jpg begin 644 visual0001.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# 4#! 0$ P4$! 0%!04&!PP(!P<' M!P\+"PD,$0\2$A$/$1$3%AP7$Q0:%1$1&"$8&AT='Q\?$Q)!P>'Q[_ MVP!# 04%!0<&!PX(" X>%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P 1" 6V! # 2( A$! Q$!_\0 M'0 ! (" P$! $$ P8"!P@%"?_$ %H0 0 ! @(%!0<-#0,, M @(# ! @,$!081$C%!!P@389,6559QL<+2%Q@A-#=14W."E+*SX105(C(V M(C0S.5)"9D_\0 &P$! (# 0$ M $&! 4' @/_Q Y$0$ 0$$!@@% @8# 0 0(#! 6Q$14T M4H&A!A,4(3%1<=$207*1P3)A%C,U0E/A(O#Q(__: P# 0 "$0,1 #\ ]E@ M 3N02 XRXRY<'"0<98ZI M3JZ'Y7_A1MU+6D,ZN@^5_P"%"U4"Y14ST2J6Y9Z)!9HEDI8:)9: 9:7*'"ES MC<#DF'&-R8!( (E'!/%$@B=SA+E+A(,=3%7+)4PUR#%7*O<#[0 M M /C:2SJG#_*_\/G6JE_2F=4X;Y7_A\NU(+UJ5BW*G:E:M M2"U;EEH8++A(,53#6S M5,%8,%R56[.]8N*MV=X*UV=[ZFBD^SBOD><^1=G>^KHCOQ?R/.!]X M M 'PM+)U3A?E_^'RK,OIZ7;\+\OS7R M;,@O696K4J5F5NT"U;9Z%>VL4 RT,D,=+)&X'.$N,;W($P$;@ $(E*) M!PGBQRR3Q8Y!BJ8+C/7Q5ZP5[O%4N\5JXJ7>(*EZ=[ZVB&_%_(\Y\B].]];0 M_P#&Q?R/.!L M -?TPWX3Y? MFOD69?6TRWX3Y?FOCV07K,K=E3LK=H%JVL6U>VL6P9:66G MOBKW 5KO%3N\5R[Q4[O$%._Q?7T-_&QGR/.?(O<7U]#=^,^1YP-A M M !KNF>_"?+\U\>R^QIGOPGR_-?'L@N MV5NSO5+*W9W@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B M4HD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1 M>XOKZ&[\9\CS@;" M #7=,]^ M$^7YKX]E]C3/?A/E^:^/9!=LK=G>J65NSO!:M[EBVKV]RQ;!FH9*-TL=#)1N MD'.')QAR!,;@C< A$I1(.$[I8ZF2=TL=0,-?%7K6*^*O6"M=XJ=WBN M7>*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ :1RRZ<8C0/1O#9 MIAL!:QM=_%QA]BY3<5R\Z?WM?1XC+\/\ %X2)^E,O MG7.6?E)KF?\ ^QS3'O4X.Q'F,ZGHU>Y\9ICC/LU]72NY1X15/"/=[#'C6OE= MY1:]^D^(_99M1Y*6&OE4Y0:M^E.._9LQY(>XZ,WGYU4\_9\YZ6W7Y45,S:JHJ_QIJU?P;OHWSBHCKF/P:HCQ1+$M<"OMG&GX=/I/\ V6;8=(KA:SH^/1ZQ M_P!AW:/CZ+Z4:/Z386<3D6:X;'41^-315JKH_.HG553^V'V&IKHJHGX:HT2W M5%=-I3\5$Z8_8 >7H!T9IGR\XO(-*\SR2C1NQB*<%B*K,79QSZ#=>1WE:Q&GFDF)RF]D MEK 4V,'5B(N4XB:YF8KHIU:IIC_7_@^5M@][L:)M*Z=$1^\>[ZV&.W&WM(L[ M.O3,^'=/L[5 :QMP =+\I'+=BM$M-MZ/6<73A)MZKU6*FB:MJW37NV9 MU?C:OV-=][36N/W"RKFBJOOB=$]T_+ M@]%#SKZY'&^"F'^>SZ!ZY'&^"F'^>SZ#WJ&_;G./=X_B/#M_E/L]%#J#DJY9 M,3III=;R*[D-G!4UV:[G2TXF:YC9C7JU;,.WVOO-UM;K7\%K&B6RNE\L;Y9] M98SICP_[I <+]?1V+ES5KV:9JU>_JACLIS'G7UR.-\%,/\]GT#UR.-\%,/\ M/9]!N-0W[BAYU];*SJM:XHI\9[GJUM:;&B;2N>Z(TRV<>=?7(XWP4P_SV?0/7(X MWP4P_P ]GT&UU#?MSG'NT_\ $>';_*?9Z*'G7UR.-\%,/\]GT#UR.-\%,/\ M/9] U#?MSG'N?Q'AV_RGV>BA\G0S.*L_T4RS.J[$8>K&X:B]-J*MJ*-<:]6O MB^LU-=$T533/C#=45Q73%5/A( \O0 //6+YQF-L8J]9C17#U1;KJHU_=D^S MJF8_U.IB]=?7(XWP4P_ MSV?0/7(XWP4P_P ]GT$ZAOVYSCW/XCP[?Y3[/10Z]Y%^4:]R@6LTKO95;R_[ MAJM1$47IN;>WM>_$:M6S_%V$UMO85W>TFSM(T3#:W:\V=YLHM;*=-,_^ /A: M?Y]7HSH=F6?6L-3B:\';BN+556S%6NJ(W_M>+.B;2J**?&>Y]+2TILZ)KJ\( M[WW1YFQ7.,TFJU__9A[,>2A]HZ,WKYU4\_9\)Z6W/Y4U?:/=[('C"OE6Y0J]^E&,_931'DA% MOE5Y0;?XNE.-G\Z*:O+#U_#-XWXY^SS_ !;==RKE[O: \K1T)H]SC<)75%O/]'KMF.-W!W8K_Z*M7TI=H:(\HNAVE%RBQE.=6:L M55NPUZ)M79GWHIJU;7[-;6WC#+U=^^THG1Y^,8TT4=WG/2,?RZ)JF;.8X3!Q/"S@Z)U?\\5/DWN5GE$NS,U:48J-?^I;MT^2 MF&RIZ-7J?&JF/O[-55TLN<>%-4\(]WLT>,+7*MRA6I_!THQL_G4T5>6%RSRS M\I%OV.Z+;CWJ\'8GS-:9Z,WGY54\_9$=+;I\Z*N7N]ACRIE?+]IUA9B,53E> M/CCTN'FF?^BJF/X-JROG(;J&Q?FU4_P#EC6G1^^T>%,3Z3[Z&59=) M;A7XU3'K$_C2] BKE&.M9GE.#S*Q%46L78HOT15OBFNF*HU_LE:::8F)T2WT M3%4:8 $) :[IGOPGR_-?'LOL:9[\)\OS7Q[(+EEWN6+8,U#)1NECH9*-T@YPY.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!A MKXJ]:Q7Q5ZP5KO%3N\5R[Q4[O$%.]Q?7T-WXSY'G/D7N+Z^AN_&?(\X&P@ M Z:YW'Y 99^M*/JKKS"]/<[C\@,L_6E'U5UYA7[H]L4>LN;=)]OGT@ ; MQ7@%^G)J?X/,U1'C+U33-7A"@+&+P.-PD1.*P>(L: M]W2VII\JNF)B?!$Q,=T@"4,^!QF+P&*HQ6!Q5["XBW.NB[9N3173/5,>S#OC MDFY=;G36C]L;Y= ##OEQL;W1\-I''YPSKC MB-O@7/+]4 M^0\3\L'NHZ1_K"[Y7MAXGY8/=1TC_6%WRMUT8_GU^GY:#I=L]'K^&J +JH([ MCYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T]&UP3;[+U>H '-W50 'CO MG$>[)GWCL?\ ;VV@-_YQ'NR9]X['_;VV@.GW#9;+Z8R^B]9O)G-?]U?#_HE[Z+UFHG2/:X](_+HO1789^J?P,6-]IW_ M (NKR2RL6-]IW_BZO)+0T^*R3X/ (#K+BP #TIS0OR7SO]-H^A#N]TAS0OR7 MSO\ 3:/H0[O _P!/LO3\R.MNY%F7 MQUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVCGZOM>1M35>1_W+M'/ MU?:\C:G++U_/K]9S=AN>SV?I&0 ^#) >!AN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;=:<,H M=1Z/?TZSXYR-)Y=?,@'47( 7,/E6:8FS3>P^6XR]:J_%KMV*JJ9X>Q,0C$Y9F6&HZ3$Y? MB[-$?Y5RS53'\8>?CITZ-+W\%6C3H5 'IX$TS--454S,3$ZXF." ';/)ERVY M]H_=LX'2"N[G&51,4S57.O$6H]^FJ?QHCWJOV3#TYD.;Y=GF48?- M(IVK=RGC[\3&^)C=,3[,2\%.R^0+3^[HCI+1E^.O3]Y]5U>*%;Q?!:+6B;6PC15'R\_]K5@F/VEC7%C>)TTSX3/R_P!9/7 "DN@, M.-Q6&P6#O8S&7[=C#V:)KNW;E6JFBF/9F9GWGF;E6Y;LTSJ[>RO16Y=RW+8J MFF<53,TW\1'OQ.^BF>KV??F/9A]KG4Z:W.GM:%8"[--N*:;^833/XTS[-%N> MJ/8JGQT^\Z!7# \(HZN+Q;1IF?"/RHW2'&[3K)NUA.B(\9\Y\DU3-4S55,S, M^S,SQ0"U*< ]LUJF/X50[%M8KXJ]8*UWBIW> M*Y=XJ=WB"G>XOKZ&[\9\CSGR+W%]?0W?C/D><#80 =-<[C\@,L_6E' MU5UYA>GN=Q^0&6?K2CZJZ\PK]T>V*/67-ND^WSZ0 -XKP]Z:.?D]EWZ):^A# MP6]Z:.?D]EWZ):^A"J=*/T6?'\+ET/\ UVOI'Y7;E%%RBJWF?)'H7I'8N3&66LLQE43LXG!4Q;F)]^:8_!JZ]<:^N&_"K6-O:V%7Q6=4 MQ/[+C;W:RO%/PVM,3'[O$7*-H5FVA&?3EF91%RW7&WAL31$Q1?H]^/>F.,<. MN-4SK+V1R[Z,VM)>3C,:>CB<7@*)QF&JU>S%5$3-5/RJ=J-7OZO>>-U_PB_S M?;#XJOU1W3[N:XWAL7"\?#3^F>^/;@ -JTRQEF-Q.6YEALPP=R;>)PUVF]:K MC_)JIG7$_P",/=6C&:V<\T=R_.;$:K>,PU%Z*=?XNU&N8_9/L?L>#7K;FR9A M5C>2C"V:JIJG!8F]A]<^]M;NQ^4QI MXQ_Z[->)^6#W4=(_UA=\KVP\3\L'NHZ1_K"[Y6!T8_GU^GY;+I=L]'K^&J + MJH([CYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T]&UP3;[+U>H '-W50 M 'COG$>[)GWCL?\ ;VV@-_YQ'NR9]X['_;VV@.GW#9;+Z8R^B]9O)G-?]U?#_HE[Z+UFHG2/:X](_+HO1789^J?P,6- M]IW_ (NKR2RL6-]IW_BZO)+0T^*R3X/ (#K+BP #TIS0OR7SO]-H^A#N]TAS M0OR7SO\ 3:/H0[O _P!/LO3\R.MN MY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVCGZOM>1M35>1_W M+M'/U?:\C:G++U_/K]9S=AN>SV?I&0 ^#) >!AN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;= M:<,H=1Z/?TZSXYR-)Y=?,@'47( 'L7F\>XYD/YM_Z^XWYH/-X]QS(?S;_U]QOSF%_VJU^J M M#Q8S/!W\OS+%9?B:=F_AKU=FY'O54S,3_&%=T.)B8TPYA,3$Z) $H>Q^0/2* MO2/DSR^]?KFO$X+7@K]4SKF9HB-F9ZYHFB9ZYEOCS_S/LPJFC2'*ZJ_P8FSB M+=/7.U35/\*'?6.FJ,#?FC\:+=6SX]4N;8I818WRNB/#3GWNK8/>9M[C9VD^ M.C1]N[\/#6FV:UYYIAFV;U5;7W5B[ERGV=U&U.S'[(U0^.#H]%$44Q3'A#EE M=RZS-.K5.7J\3>JK.J9BF/"/DZ/T=N=VBYTV MM-,35/C/S\?#]E:K+\!5&JK X:8Z[5/]%/&Z-:.XVW-O&9#E6(IGA=PENJ/X MP^J-)%I7'A*P39T5=TQ#0LXY'N3W,J9VL@MX6N=U>%NUVIC]D3L_P:%I-S<\ M)5;JN:-Y]>MW.%G'4153/RZ(B8_Y9=]#-L<5O=C^FTGCWYM?;X-/^5G'# MNR=?<@FC6=Z)Z'XK)L]L6[=ZC'UUV:K=R*Z:[M8KXJ]8*UWBIW>*Y=XJ=WB"G>XOKZ&[\9\CSG MR+W%]?0W?C/D><#80 =-<[C\@,L_6E'U5UYA>GN=Q^0&6?K2CZJZ\P MK]T>V*/67-ND^WSZ0 -XKP]Z:.?D]EWZ):^A#P6]Z:.?D]EWZ):^A"J=*/T6 M?'\+ET/_ %VOI'Y7P%07APO6Z+UFNS_$^Q+P!73LUU4Z]>J=3W MMGF-HRW)<=F-R8BC"X>Y?JF>$4TS5/D>")]F5NZ+1.BUGY=WY4GIA,:;*/G_ M ,OP +8I8].\T:J9T!S2CA&:53'[;5O^CS$]4-,,2_V%5XN]=E3XS#-PZ\4W:]46M?A M$O^V'^9VOZ*A_#5[\Z?O/LN_\5W+RJ^T>[UT M/(OJX_.G[S['\5W+RJ^T>ZKSB/=DS M[QV/^WMM ?2TFSS,=(\\Q&IO8W$[/2UTT13$[-,4Q[$>Q'L4P^:N=ULI MLK"BSJ\8B(^T*)>[6FVO%=I3X53,_>0!]V,[0YK_ +J^'_1+WT7K-Y,YK_NK MX?\ 1+WT7K-1.D>UQZ1^71>BNPS]4_@8L;[3O_%U>265BQOM._\ %U>26AI\ M5DGP> 0'67%@ 'I3FA?DOG?Z;1]"'=[I#FA?DOG?Z;1]"'=[G&,[=:>OX=3P M'^GV7I^9'6W.6]R+,OCK'UM+LEUMSEO10'37) 'MGD?\ OY]?K.;L-SV>S] M(R 'P9( #P+FO]J8OXZOZ4JRSFO]J8OXZOZ4JSK%/Z8<7J_5( ]/+T-S._:N MDWY^&\EUWZZ"YG?M72;\_#>2Z[]<[QS;K3AE#J/1[^G6?'.1I/+K[DFD'Z/3 M]92W9I/+K[DFD'Z/3]92PKEM-G]49LZ_[+:_3.4O&0#J+D #V+S>/<4S2'%6YVJ)QURBF??BB=B)_Z6KNI72) MBPHB?'1&3CU\F)O%I,>&F=>9]A:JLSTBQNK\&W9L6O'-554^:]%.?8_.F_5<,G3.C5,QA]&GSG. M7@W2C+:\GTDS+*;E,TU8/%7+.J?>IJF(G_"'SG=G.GT.N8#/[6EN#M3.$Q\1 M;Q6S'XEZF-43/553$?MIGWW2:[7&\Q>;"FTCYQW^OS4#$+I5=+S793\I[O3Y M #+83/E^,Q>7XVSC<#B+N&Q-FJ*[=VW5--5,QQB8=[Z"Y M]&-+M&M);,7,CSG"8RJ8US:IKU7:8ZZ)U51^V'W'Y_V;MRS=INV;E=NY1.NF MNB=4TS[\3#L#1'EDTXT?FFW7F7WUPT;[./UW)U=5>O;C_'5U*U>>C-<=]A7I M_:??_P 6NZ=+:*NZ\4:/WCV_]>P!U)H3R\Z+YS71AMWK-RG:HN6ZHJIJCWXF/8F%>O%TMKM5\-K3H6 M>ZWVPO=/Q6-43_WR\60!CLH !KNF>_"?+\U\>R^QIGOPGR_-?'L@N6 M5RSO4[*Y9W@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B4 MHD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1> MXOKZ&[\9\CS@;" #IKG'O31S\GLN_1+7T(>"WNW1W&X*-'\NB<7AXF,+:UQT MD?ZD=:J])XF:;/1^_P"%QZ(3$5VNG]OR^L/DYGI-H[EE,U9CGN682-6O_P"; M%44S/BB9]EUKIYR\Z.97AKF'T:B+Q.BSHF['WPS:-FJF)]FW8B? MPJI_.U;,>_KJ]YY7?0TASG,L_P WOYKF^*KQ6+OU:ZZZOX1$;HB.$1N?/= P MRXQ)^6#W4=(_UA=\KVP\3 M\L'NHZ1_K"[Y7QZ,?SZ_3\OOTNV>CU_#5 %U4$ !VAS7_=7P_P"B M7OHO6;R9S7_=7P_Z)>^B]9J)TCVN/2/RZ+T5V&?JG\#%C?:=_P"+J\DLK%C? M:=_XNKR2T-/BLD^#P" ZRXL ]*Y%F7QUCZVEV2ZVYRWN19E\=8^MI?'#MK MLOJC-D8IL5K],Y/(H#IKD@ #VSR/^Y=HY^K[7D;4U7D?]R[1S]7VO(VIRR]? MSZ_67H;F=^U=)OS\-Y+KOUT%S._:NDWY^&\EUWZYWCFW6G#*'4>CW].L^.< MC2>77W)-(/T>GZRENS2>77W)-(/T>GZREA7+:;/ZHS9U_P!EM?IG*7C(!U%R M ![%YO'N.9#^;?^ON-^==\WS%X6WR/Y%1]'XT]42U[2_EKT*R.Q73@L;.= M8R(_ LX3V:)GAKN3^#$>+7/4\U\H6FN=:;9S]\,VNQ%NC73A\-;_ /QV*9X1 M'&9]C7,^S/BB(C889@MM;VD56M.BB//YM9BV/6%VLYHL:OBKGR^7[_Z:Y_'O3$^S$\)B'D M;E7Y,LXT(QU=^**\9DMRO58QE,:]G7NIN:OQ:OX3PXQ'L9CQ-BSB*X198A1_R[JH\)]_V M> !Z7Y0.0'*LQJN8W13%4Y7B*M*=4KM=,4NUZC_A5W^4]T_P#?1S^^X/>[G,_' M3ICSCOC_ %Q:R V+5@ #<>3CE&TBT)Q=/W!B)Q&7S5KO8&]5,VZ_?FG_ %*N MN/VZ]S3A\K6QHMJ)HM(TQ+ZV-O:6%<5V2=TMA>)N2W3+&:%:5V,TL357A:YBWC+$3[%VU,^S^V-\3[\>] M,Z_:N$Q%G%86UBL/_"?+\U\>R^QIGOPGR_-?'L@N65RSO4[*Y9 MW@M6]RQ;5[>Y8M@S4,E&Z6.ADHW2#G#DXPY F-P1N 0B4HD'"=TL=3 M).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\04[W%]?0W?C/D><^1>XOKZ&[\9\ MCS@;" #IKG 'T=&\ES+2'.FN3K0+(=",MG#Y79FYB;D1] MT8R[$3=NSX^%/O4Q['CGV6EQ'&K&ZQ--$_%7Y>7K[-_A> 6]\JBJN/AH\_/T M]_!QY*]"<%H-HQ1EEBJF]B[L])C,1$:NEN=7^[&Z(_;OF6V H=K:UVMZCI'^L+OE>V'B?E@]U'2/]87?*L/1C^?7Z?E6. MEVST>OX:H NJ@CL3D!T1R?3+2[&9;G=%ZO#VL!5?IBUY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_P"Y=HY^K[7D M;4U7D?\ GEZ&YG?M72;\_#>2Z[]=!#F=56,Q&NBS M'BG?5XJ8E\[6UHLJ?BKG1#ZV-C:6U?P6=,S/[-6PF&Q&+Q5K"X6S55YEFE--6>8RC5=B)B8P]O7KZ.)XS[$35/ MOQ$1NUS?Y*^2S)-![?W5K^^.;U1JJQERC5L1QIMT^SLQU[Y]_5[#?U+Q?&NT MQ-C8_I^<^?\ I?<#P#LD]?;_ *_E'E_L 5U: F(F-4[@!HNEW)+H1I'-=V M_E-.!Q5>_$8*>BJU^_,1&S,](TST%<1:OQ'5K M_!J_QCQ/3@V=UQ>]W;NIJTQY3WM3>\$N=ZTS51HGSCNGV^[P%CL)BL#C+N#Q MN'NX;$6:IIN6KM$TU43[TQ.YA>MN<#H-E^D6AV-SBW8MV\VRVQ5?MWZ:=55R MW1$U56ZO?C5$ZO>G5[\Z_)*[8;B%-^LOCB-$QXPY_BN&5X?;?!,Z8GOB0!L6 MK'KWFXYO%,ZZ8_9353'['D)Z?YH^UZGV9:_Q?OK M7J\?16M?_AH>D=$57/3/RF%DZ+6DTW[X8^<3[NY %#=& :[IGOPGR_- M?'LOL:9[\)\OS7Q[(+EEWN6+8,U#)1NECH9*-T@YPY M.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!AKXJ]:Q7Q5ZP5KO%3N\5R[Q4[ MO$%.]Q?7T-WXSY'G/D7N+Z^AN_&?(\X&P@ Z:YW'Y 99^M*/JKKS"] M/<[C\@,L_6E'U5UYA7[H]L4>LN;=)]OGT@ ;Q7AW'@>;WI+B\%8Q5&=9133> MMTW*8F;FN(F-?^JZ<>]-'/R>R[]$M?0AH<=8YN>D^OV<\R>(ZND]%9PO-PS>JN(Q.DN!M4\9MX>NN?\)F'I M 5V>D%^G^Z/M"TQT:P^/[9^\NE,GYNFCUBJ*LUSS,<;J_P FS139IGQ_C3_% MV#HQR=:&:.337E>0X6+]/LQ?O1-VY$^_%5>N8_9J;4,*VQ&]6\:*ZYT?;)GW M?"[G=YTV=G$3]Y^\@#"9X \3\L'NHZ1_K"[Y7MAXGY8/=1TC_6%WRK+T8_G MU^GY5/I=L]'K^&J +JH([CYH_NAYE^J;GUUITX[CYH_NAYE^J;GUUIK<7V*T M]&UP3;[+U>H '-W50 'COG$>[)GWCL?]O;: W_G$>[)GWCL?]O;: Z?<-ELO MIC)R+$MLM?JJSD 9;"=HY%F7QUCZVE\<.VNR^J,V1BFQ6OTSD\B@.FN2 /;/(_[EVC MGZOM>1M3PO@]+]+,'A;>%P>D^=X?#VJ8IMVK6/NT444QNB(BK5$,O=SIKX7Z M0?\ [*]Z2H6W1NUM+2JN*X[YF5WL.E=C9V5-$V<]T1'C'R>XQX<[N=-?"_2# M_P#97O2.[G37POT@_P#V5[TGS_ABU_R1S?7^+K'_ !S]X>XQUKS<+F;XODXI MS/.!A MN9W[5TF_/PWDNN_707,[]JZ3?GX;R77?KG>.;=:<,H=1Z/?TZSXYR-)Y=?JF8WTR^U'-STGU^SGF3ZOWGHNV M^;Q[CF0_FW_K[C?E'O>.7RSMZZ*9C1$S'AY2Z%2MF8=315>J*:XTQ,Z/OW,'$ZK2BZ6E5 MG.B8C3]N]2T2Y>M$,UIHM9O3B,DQ,^Q/2T]):U]5=,:_\8AV?E699=FN$IQ> M68[#8W#U;KMB[%=/^,2\#+.6YAC\MQ$8C+L;B<'>C=>C5C M7WV-4T\X]\U/NO2RWH[K>F*OWCNGVR>^AXYRCEAY0LNU4TY_7BJ(_P G%6J+ MNOY4QM?Q;+@NK^#4VG1R]T_IF)X^[TO4(\XTIB9F9\7OP\:OIZ1Y_G.D68U9AG>8W\=B9 MC5%5RKV*8]ZF(]BF.J(B'S%MPK#NPV4TS.F9\5+QC%-86T5Q&BF.Z !LVH'K M;FQY=5@>2G#7JJ9IG'8F[B-4^]KBB)_PMP\L:/93C,\SS!Y1E]N;F)Q=VFU; MC5NU[YGJB-(I ML:;&/&9T\(6WHE=IJMJ[>?"(T<9_UFO *8OH #7=,]^$^7YKX]E]C3/? MA/E^:^/9!IV5RSO!:M[EBVKV]RQ;!FH9*-TL=#)1ND'.')QAR!,;@C M< A$I1(.$[I8ZF2=TL=0,-?%7K6*^*O6"M=XJ=WBN7>*G=X@IWN+Z^ MAN_&?(\Y\B]Q?7T-WXSY'G V$ '37.X_(#+/UI1]5=>87I[G*\/>FCGY/9=^B6OH0\%O>FCGY/9=^B6O MH0JG2C]%GQ_"Y=#_ -=KZ1^5\!4%X 'B?E@]U'2/]87?*]L/$_+![J. MD?ZPN^59>C'\^OT_*I]+MGH]?PU0!=5!'KU YNZJ \=\XCW9,^\=C_ +>VT!O_ #B/=DS[ MQV/^WMM =/N&RV7TQDY%B6V6OU59R ,MA.T.:_[J^'_1+WT7K-Y,YK_NKX?] M$O?1>LU$Z1[7'I'Y=%Z*[#/U3^!BQOM._P#%U>265BQOM._\75Y):&GQ62?! MX! =9<6 >E.:%^2^=_IM'T(=WND.:%^2^=_IM'T(=WN<8SMUIZ_AU/ ?Z?9 M>GYD=;Y.\J^_>G62Y7-.U1?QMN+D?[D5:Z_^F)>+2N**9JGPA[L[.;2N M*(\9G0]D30?)XYD/YM_Z^XWYS"_[5:_5.582=4U8C'4S;]C_=HF-JK_#5UP]" M\FG)3HYH5-.,MQ5F.:ZM4XR_3'X'O]'3NH\?LSUM3?<:NUUB8B?BJ\H_,MUA M^ WJ^3$S'PT^<_B/GD^#S?>3&O17"3G^>68C.L31LV[4^S]RVYX?GSQ]Z/8] M]VX"B7J]6EZM9M+2>^71KG=+.YV,65G'='_=( QV2 UW3/?A/E^:^/9 M?8TSWX3Y?FOCV07+*Y9WJ=EY8MJ]O*G=XKEWBIW>(* M=[B^OH;OQGR/.?(O<7U]#=^,^1YP-A !AQF$PN,MQ;Q>&LXBB)VHIN MVXJB)]_5*K]XLD[SY?\ -J/Z/H#U%=4=T2\S13/?,/G_ 'BR3O/E_P VH_H? M>+).\^7_ #:C^CZ GK*_-'54>4/G_>+).\^7_-J/Z+]----,4TQ%-,1JB(CV M(A(B:IGQE----/A \O0 I7LGRF]=JNWLKP-RY7.NJNO#TS,S[\S,+H MF*ICPE$TQ5XP^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H#UUE?F\]51Y0^? M]XLD[SY?\VH_HS8/+]KB.I:$375/=,D6=$= M\0 /+V IXG*.(6P>9F9\7J*8I[H"8B8U3&N 0E\_P"\62=Y\O\ MFU']#[Q9)WGR_P";4?T?0'OK*_-XZJCRA\_[Q9)WGR_YM1_0^\62=Y\O^;4? MT?0#K*_,ZJCRA@P>#PF#HJHP>%L8>FJ==46K<41,]>IG!YF9GQ>HB(C1 QXG M#X?%69LXFQ:OVIWT7*(JIG]DL@B)T>"9C2^?]XLD[SY?\VH_H?>+).\^7_-J M/Z/H#WUE?F\=51Y0^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H!UE?F=51Y0 M^?\ >+).\^7_ #:C^A]XLD[SY?\ -J/Z/H!UE?F=51Y0^?\ >+).\^7_ #:C M^C)ALIRO#7J;V'RW!V;M/XM=NQ335'#V)B%P.LJGYD6=$?( >'M\^?+_FU']'T![ZROS>.JH\H?/^\62=Y\O^;4?T/O%DG>?+_FU']'T ZROS.J MH\H8\-8LX:S39P]FW9M4_BT6Z8IICC[$0R \>+W$: !2S+*N MNS'^%%40^1B.0GD^NZ]C!XZQ^9BZI^EK=G#+IQ"]4>%I5]Y85>&7.OOJLJ?M M#J&[S>="*ZM=./SZW'O4XBUJ_C;ERPW-\T'M5:[F*SN_'O7,31$?]-N';@^F MM;YHT=9+Y:FN&G3U4.OQ[[.B(](@ M ?!D@ -;TTJ_^7!4^_%R?HODV7T--:XG,\%;U^S39N53'CFC^CY] ME*(7+*Y9WJ=EY8MJ]O*G=XKEWBIW>(*=[B^OH;OQG MR/.?(O<7U]#=^,^1YP-A M ! MUQI-C*[G*ABL%MZ[=C)\-7$>]57>OZ_X4TKMEHN4YG3FG+CIY7:O=+:P\83" MT>S[%,VZ*J:Z?V5Q6WJR^]XH^"J(_:,HEC76TZRB:OWJY3,+EE*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXS MY'G V$ M !7S/&X?+O5SNIHIB9F?\ "%AU7SH])?O#R68K!V;LT8O-[D8.WLS&N*)_"N3J MGALQ-,_GP^UWLIMK6FSCYR^%YMHL+&JTGY0ZGYNF87\VTFTLS7%;/3XVY1B+ MNSNVJZ[E4ZOVR[RLN@N:U[=S[XNQY:W?MEF8O$1>ZHC]LH8&!S,W*B9_?.5R MRN6=ZG97+.]K6V6K>Y8MJ]O*G=XKEWBIW>(*=[B^OH;OQGR/. M?(O<7U]#=^,^1YP-A M >.N=- MI;&D7*/7EF&N[>!R2F<+1JG7$WIG7=J_QB*/W?6])%;MRY=NUW;M=5RY75-5554ZYJF=\S/& M5AP*ZZ:IMZOEW1^57Z1WS13%WIGQ[Y_#N;FM>W<^^+L>6MW[9=!*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ M M !CQ-^SAL-=Q.)NV[-BU1-=RY)BK T5:LQQ5N=?351/_ .*F?]6)CV9XS[&Z)VLJYW2N M]6D44\9\F'?K[1<[*;2OA'G+0.7?E KT]TRKQ&&KJC)\%KLY?1,3&NG7^%VKM[2;2N>^7<_-;]NY]\78\M;O MVRZ"YK?MW/OB['EK=^V5.QC;*^&4+U@6PT<*G=X@IWN+Z^AN_&?(\Y\B]Q?7T-WXSY'G V$ M M F8B-4>6SEMS'2_ILDT?Z;+LAG71[3X[2?]) M9+$=S\UOV[GWQ=CRUN_;+H+FM^W<^^+L>6MW[94K&-LKX90Z!@6PT<*G=X@IWN+Z^AN_&?(\Y\B M]Q?7T-WXSY'G V$ M ?,T@T@R/1_#1B<\ MS? Y=:G7LSB+U-&WJ]G53$SKJGJC7+IW37G)Z.8"BY8T6R_$9QB-U-^]$V+$ M>QOU3^'5JG5[$Q3XV1872VMY_P#G3IR^[%O%]L+M'_TJB,_L[TKJIHIFJJJ* M::8US,SJB(=.\IO+]HUH[3=P.CLT9]F<1,17;J__ (MJ=6^:X_'X>Q1UQM1+ MSGI]RFZ8Z:U56\YS6NG!3.N,%AHZ*Q&Z?9ICV:M4QKB:IJF.#3F_NF!4T_\ M*WG3^T*U?>D=56FF[QH_>?'[/OZ;Z8Z0Z99K.8:09AY8MJ]O*G=XKEWBIW>(*=[B^OH;OQGR/.?(O<6HZ;\J^6\F,X M7[X95B\?]\MO8Z"NFG8Z/5KUZ_?VX_P>[.SJM:HHHC3+Q:6E-E3-5WMGKK] M'?!3->WMFK;UN9&L;MOYO18\Z>NOT=\%,U[>V>NOT=\%,U[>V:MO6YDC65UW M\WHL>=/77Z.^"F:]O;/77Z/>"F:]O;-6WKBQYU]=?H]X*9KV]L] M==H]X*9IV]LU;>MS(UE==_-Z*'G7UUVCW@IFG;VSUUVCW@IFG;VS5MZW,C65 MUW\WHH>=?77:/>"F:=O;/76Z/>"F:=O;-6WKBAYV]=;H]X*9IV] ML]=;H]X*9IV]LU;>MS(UE==_-Z)'G;UUNCW@IFG;VSUUNCW@IFG;VS5MZW,C M6=UW\WHD>=O76Z/>"F:=O;/76:/>"N:=O;-6WKB1YV]=9H]X*YI MV]M/KK-'_!7-.WMFK;UN9&L[KOYO1 \[^NLT?\%V>NKT?\%V:MO6 MYDC6=UW\WH@>=_75Z/\ @KFG;VSUU>C_ (*YIV]LU;>MS(UG==_-Z('G?UU> MC_@KFG;VSUU>C_@KFG;VS5MZW,C6=UW\WH@>=_75Z/\ @KFG;VT^NJT?\%V:MO6YD:TNF_F]#CSQZZK1_P %V>NJT?\ !7-.WMFK;UN9&M+IOYO0 MX\\>NJT?\%@]=3H_X*YIV]LU;>MS(UI=-_-Z''GCUU.C_@KFG;VT^NIT M?\%V:MO6YD:TNF_F]##SSZZG1_P5S3M[9ZZG1_P5S3M[9JR];F1K2Z;^ M;T,///KJ='_!7-.WMGKJ='_!7-.WMFK+UN9&M+IOYO0P\\^NHT?\%LT[>A/K MJ-'_ 6S3MZ#5EZW,D:TNF_F]"CSUZZC1_P6S/MZ#UT^0>"V9]O0:LO6YD:U MNF_F]"CSUZZ?(/!;,^WH/73Y!X+9GV]!JR];F1K6Z;^;T*//7KI\@\%LS[>@ M]=/D'@MF?;T&K+UN9&M;IOYO0H\]>NGR#P6S/MZ$^NGR#P6S/MZ#5EZW,C6M MTW\WH0>>_739!X+9GV]!ZZ;(/!;,^WH-67KA!Y[]=-D'@MF?;T) M]=+D'@MF?;T&K+UN9&M;IOYO08\^>NER#P6S/MZ#UTN0>"V9]O0G5EZW,C6M MSW\WH,>?/72Y!X+9GV]!ZZ7(/!;,^WH-67K@QY\]=+D'@MF?;T' MKI<@\%LS[>@U9>MS(UM<]_-Z#'GWUTF0>"V9]O0>NDR#P6S/MZ#5EZW,D:VN M>_F]!#S[ZZ3(/!?,^WH/71Y!X+YGV]!JR];F1K:Y[^;T$//OKH\@\%\S[>@] M='D'@OF?;T&K+UN9&MKGOYO00\^^NCR#P7S/MZ#UT>0>"^9]O0:LO6YD:VN? M^3-Z"'GWUT>0^"^9]O0GUT>0^"^9]O0:LO6YD:VN?^3-Z!'G[UT60^"^9]O0 M>NBR'P7S/MZ#5EZW,C6US_R9O0(\_>NBR'P7S/MZ$^NBR'P7S/MZ#5=[W,C6 M]S_R1S>@!Y_]=#D/@OF?;T'KH@U7>]S(UO<_\D?_70Y#X+Y MGV]!ZZ'(?!?,^WH-5WOY_Y,WH >?_70Y#X+YGV]!ZZ'(?!?,^WH-5WO MN<>%4SPEZY'BC%\O'*A M?N554:148>FK_(M8&QJCQ3-$S_%KN9G ;>?U51'W]F+7TDN\?IIF?M[O=^9YEE^5X6K%9GC\+@L/3^-=Q%ZF MW1'CFJ8AH^?\M7)MD]5=NYI)9QEVFG:BC!6ZK\5=45TQL:_'4\17KER]=JNW MKE=RY7.NJJJ=[;NJKT1^W=DS8S%8K&XJYBL9B+ MV)Q%R==R[=KFNNJ??F9]F6$2SXC0UTSI 2E "0 ! (=S\UOV[GWQ=CRUN_; M+H/FN>W<^^+L>6MWY94K&-LKX90Z#@6PT<*G=X@IWN+SMSPO[L>/%_R7HF]Q>=N>#_=C_B_Y+88 M5M5''*6!BFRU\,X>?T@N"H @!(@!( )$"4)$"4) $) 3 D$I0 " !*$ M@)0D0)@ ! "1 "2 !*0!(@!(@ $"0 2 "2!,( $H 2 "1! ) @$@ " 0 M) !()A D!"0 $H2($H3 "4)$"4)$ "8$D E"0 2 ( ! E"0=S\USV[GW MQ=CRUN_++H/FN>W<^^+L>6MWY94K&-LKX90Z#@.PT<*G=X@IWN+SMSP?[L?\7_)>B;W%YWYX/\ M=C_B_P"2V&%;51QREK\4V6OAG#S^ N"H )$ ) !( )$ )$ @3 0F 2"02 M \@ ) !," $@ #R) @$@D$@($@(3 )$ ) 2A*80 )0 D $@"$@ D M 0 "!*$@)0D!,(2EY$@ "1 "0 2 "1Y $@D$P@2 "0 'D!, D'Y8MJ]O*G=XKEWBIW>(*=[B\[\\'^['_%_R7HB]Q>=^ M>#_=C_B_Y+885M5''*6OQ39:^&) !, D! D! D ! "0 2D$H2E M ( 2 (2 "0 ! E"1 E"4P"4)$"4)$"0 !(@!( )2 "7D 2 "0$"0 2 M \@) !( )3" $B 0) !( ) 0) 0 )A"4P@2A*02A( @ $) !( AW/ MS7?;N??%V/+6[[LNA.:[[=S[XNQY:W?=E2L8VROAE#H. [#1QSEIV5 MRSO:QN%JWN6+:O;W+%L&:ADHW2QT,E&Z0M8KXJ]8*UWBIW>*Y=XJ=WB"G>XO._/!_NQX\7_)>B+W% MYWYX/]V/'B_Y+885M5''*6OQ39*^&IV5RSO:QN%JWN6+:O;W+%L&:ADHW2QT,E&Z0M8KXJ]8*UWBIW>*Y=XJ=WB"G>XO._/!_NQX\ M7_)>B+W%YWYX']V/'B_Y+885M5''*6OQ39*^&<.@ 2N"G@) !(\@) $"0 M3 )!() >0 $@ D0 D >1($"0$B0@$) $) $"4) A*$@)!,( $H 2" M0 2( 2 ( ! D( 2! )!+R) $B $@ D $CR )!()0) !( #R D $@) M0D0)0F!#N7FO>W<]^+L>6MWW9="UC<+5OWN6+8,U#)1NECH9*-T@YPY.,.0)C<$;@ M $(E*)!PG=+'4R3NECJ!AKXJ]:Q7Q5ZP5KO%3N\5R[Q4[O$%.]Q>=^>!_=C MQXO^2]$7N+SOSP/[L>/%_P EL,*VJCCE+7XILE?#.'0"07!3Q("$@"$@ "! M*$D E"7H$H2( ! "0!"02! @2 @2"02 @2 @2 )$ ) !,)A E MD $P @3 ) 0 " $@ D $I0)0D0 "$@ D( 2 (2 ( $H2F$$)0E()0D M0 "$@ D$B $B $@[EYKWMW/?B['EK=]670O-?]NY[\78\M;OJRI6,;97PRAT M+ =AHXYRN65RSO4[*Y9WM8W"U;W+%M7M[EBV#-0R4;I8Z&2C=(.<.3C#D"8W M!&X !")2B0<)W2QU,D[I8Z@8:^*O6L5\5>L%:[Q4[O%XO/'.__ +L>/%_R6PPK:J..4M?BNR5\,X= )!<%.$@( M$@ "1 "4@"4H ! D $D @2 @!(@!*8 $@ D>1,(2 ($@ D 2 ]/ M( E"0$H2($H2 E"0 !Y 2 "0$PA, D0 ) 0) !("!(" $I@ 2E "0 M ! ($D "0 2 \B0 2 .Y>:_[=SWXNQY:W?5ET+S7_;N>_%V/+6[ZLJ5C&V5 M\,H="P'8*..Y8M@S4,E&Z6.ADHW2#G#DXP MY F-P1N 0B4HD'"=TL=3).Z6.H&&OBKUK%?%7K!6N\5.[Q7+O%3N\0 M4[W%YXYW_P#=CQXO^2]#WN+SQSO_ .['_%_R6PPK:J..4M?BNR5\,X= @E<% M- 2 ($@F!("02 \@ )@!*$B!*$@ #RD @2 D2 (2"1 ($@ D $@ MF$ "4 ) !(@!( ) $ @2 "0(0)!*!( D0 D $@ D>0 !(F $H2 "0! M ($H2 E"0$H2($H2($H2 F$.Y>:_[=SWXNQY:W?5ET+S7_ &[GOQ=CRUN^ MK*DXQME?#*'0\ V"CCG*[96[.]4LK=G>UC<+5OWN6+8,U#)1NECH9*- MT@YPY.,.0)C<$;@ $(E*)!PG=+'4R3NECJ!AKXL%QGKXL%P%6[Q4[O% M:_P"W<]^+L>6MWU9="\U_V[GO MQ=CRUN^K*D8QME?#*'0\ V"CCG*[96[.]4LK=G>UC<+5OWN6+8,U#)1 MNECH9*-T@YPY.,.0)C<$;@ $(E*)!PG=+'4R3Q8Z@8J^*O<6*^*O6"K M=XJEUXO/'.__NQ_Q?\ );#"MJHXY2U^ M*[)7PSAT"D%P4T !(@!*0!*4 @ 2 "0$"0 $ )$"4)3 )0F $H2/(E"0 M !"2 !() >GD 2A("0$"0 2A( \@) "$@ E,( 2( ! D $@ D! D! M "4P@!*0!( @ $"0 2 ) 'E(0 ) @ 'I E"0=R\U_V[GOQ=CRUN^;+H;F MO^W<]^+L>6MWS9A2,8VROAE#H> [!1QSE=LK=E4LKEIK&X6;:Q;5[:Q;W S4 M,E&Z6.ADIW YPY.,.0)C<$;@ $(E*)!PGBQRR3Q8Y!BKXJ]Q8J8+@*M MU4N\5R[NE4O3O!2O1O>>.=__ '8_XO\ DO0][B\\<[_^['CQ?\EL,*VJCCE+ M7XKLE?#.'0("X*: "$@)@2 D2 /( E"0$H2($PA( @!(@!) E( D0 D0 M "!( ) !) F$ "4 ) !(@@$@0"0 ! ($@ D$P@2 A( "4)$"4)@!*$B! M*$B !,"2 2A( ) $ @2A("4) 2 @2 @2 "4 )2 )!W+S7_;N>_%V/+6[ MYL.AN:_[=SWXNQY:W?-E2,8VROAE#H> ;!1QSE=LK=I4LKEEK&X6;:Q;5[:Q M;!EH9*=S'2RT[@*I=X@I7N+SQSO_P"[/CQ?\EZ'O<7GCG?_ -V?'B_Y3885M5'' M*6OQ79*^&<.@0%P4P2"8!()!(#R D $B $@ #R) @$@D$@($@(3 M)$ ) 2A*80 )0 D $@"$@ D 0 "!*$@)0D!,(2EY$@ "1 "0 2 "1Y M$@D$P@2 "0 'D!, D $B $B $@ )A D$@ D!#N7FO^W<]^+L>6MWS8=#< MU_V[GOQ=CRUN^;"D8QME?#*'1, V"CCG*[97+*G97++6-PM6EBA7M=2Q;!EI M9(W,=#) .4;W)$)!,;@ 1Q1*91P!QEPJ9)W,=8,-3!<9ZV"YQ!5N\5 M.[Q7+O%4O<04KSSSSP-VC'CQ?\EZ'N\7GCG@;M&/'B_Y+885M5''*6NQ79*^ M&<.@ 2N"FB4)2 )2@ $ )" $A (2 ($H2($H2F 2A(@2A(@2 )$ ) M!*0 2\@ "0 2 @2 "0 'D!( ) !*80 D0 "!( ) !("!(" !,(2F$"4) M2"4) $ A( ) $) $) !(! /2!) D! D!#N7FO>W<]^+L>6MWS9AT-S7O M;N>_%V/+6[YLJ1C&V5\,H=%P#8*..TL6P9J62&. MAD@'*$HC+_DO0UW'[AN8:C[G^Z-OIJIC7M= M'JU:HG_5EGX7.B]4\III! M\-E_:U>B>III!\-@.UJ]$ZRE'4U^32QNGJ::0?#8#M:O1/4TT@^&P':U>B?' M2=37Y-+2W/U-=(/AL!VM7HI]372#X; =K5Z)\=)U-?DTM+<_4UT@^&P':U>B MGU-=(/AL!VM7HGQTO/4U^32TMS]37/\ X; =K5Z)ZFV?_#8#M:O1/CI.IK\F MF#<_4VS_ .&P':U>B>IMG_PV [6KT3XZ3J:_)I@W/U-L_P#AL!VM7HGJ;9_\ M-@.UJ]$^.E'46GDTTAN?J;9_\-@.UJ]$]3?/_AL!VM7HIBNDZBT\FFCBGU-\_^&P':U>B=92=1:>331N7J;Y_\+@.UJ]$]3C/_ (7 =K5Z M)UE*.HM/)IPW+U.,^^%P':U>B>IQGWPN [6KT3K*3J+3R:<-Q]3C/OA<#VM7 MHGJ<9]\-@.UJ]$ZRDZBT\FG#B>ISGWPV![6KT3K*4=1:>33DMP]3G/OAL#VM7HI]3G/OAL M#VE7HG64G46GDTY+BGK*?,[/:>33AN/J=9]\-@>TJ]$]3K/?AL#VE7HG6 M4^9V>T\FGCIWGOPV![2 MKT3U.\]^&P/:5>B=93YG9[3R:@-P]3O/?AL#VE7HGJ>9[\-@>TJ]$ZRGS.SV MGDU ;?ZGF>_#8'M*O1/4\SWX; ]I5Z)UE/FCL]KY-0&W^IYGOPV![2KT3U/, M]^&P/:5>B=93YH[/:^341M_J>9Y\+@>TJ]$]3S//A<#VE7HG64^9V>U\FHC; MO4]SSX7 ]I5Z)ZGN>?"X'M*O1(M*?,[-:^34AMWJ>YY\+@>TJ]$]3W//A<#V ME7HIZVGS1V:UW6I#;?4^SSX7!=I5Z*?4^SSX7!=I5Z)UM/F=FM=UJ(V[U/L\ M^%P/:5>B>I]GGPV![2KT3K:?,[-:[K44MM]3[//AL#VE7HGJ?9W\+@>TJ]$Z MVGS1V:UW6I);;ZGV=_"X+M*O1/4_SOX7!=I5Z)UM/F=FM=UJ26V>I_G?PN"[ M2KT4^I_G?PN"[2KT3K:?-'9K7=:DEMGJ?YW\+@NTJ]$[@,[^%P7:5>B=;3YH M[+:[K4QMGX M#._A<%VE7HG64^9V6UW6IC;.X#._AL%VE7HGB=;1YH[+;;K5$MK[@B=P6=?"X+M*O1.MH\SLMMNM42VKN"SKX7!=I5Z*>X+.OA<%VE7HG6T> M9V6VW6J0EM7<%G/PV"[2KT3N#SGX7!=I5Z)UM'F\]EMMUJJ6U=P><_"X+M*O M1.X/.?A<%VE7HG6T>9V2VW6JI;3W!YS\+@NTJ]$[@\Y^%P7:5>B=;1YG9+;= M:L-I[@\Y^%P7:5>B=P><_"X+M*O13UM'FCLEMNM6&U=PF<_"X+M*O1.X3.?A M<'VE7HG6T>9V2VW6K#:NX3.?AL%VE7HG<)G'PV"[2KT4];1YG9+;=:L-JC03 M./AL%VE7HG<)G'P^"_YZO1.MH\T=DMMUJPVKN$SCX?!?\]7HG<)F_P#M&!_Y MZO1.MH\SLEMNM[YKWMW/?B['EK=]673G-^T?QN2XG.*\5+S%5[KF/VRA?L#HJHN-%-4=_?G*Y96[*G97++6MLM6EBVKVEB MV#-1N9*=S'0R4@Y1N3 F .""0'&ICJW,DL=0,-;!<9Z^+! M*I=XK=WBJ7>(*=W>:WR[NEH?*=_F'[SS6=ANTT\KAF MTL!:E; M ;ER9;\?^[\YOEAH? M)EOQ_P"[\YOEGGCG*W97+*I96[3!9BU:6+:O:6* 9J&2G MWV.ADIW YD(C>:WN]Q:'RF_YA^\\UG8;M-/'*6'?]GJX9M, M6I6P M &Y["JXEM-7#*%DP_9Z>.TL4 S4,D,=+) M2#E"81"8!( (1*42#C+'4R3Q8Z@8ZE>XSU,%?$%:[NE3N\5R[Q4[O$ M%*]Q:'RF[\!^\\UOM[BT+E-WX#]YYK.PW::>.4L._P"SU<,VF +4K8 M M #WNPJ MN);35PRA9,/V>GCG*[97+*G96[+!9BU:6*%>VL4 RTLE+'2R4@YPE$)!( M (1*42#A/%CJ9)XL=0,=2O6SU[I8+G$%:ZJ7N*W=XJET%.]Q:%RF[\!^\ M\UOE[BT3E-WX#]YYK.PW::>.4L._[/5PS:6 M2M@ M M -RY,_QL?^[\]O=B&B_'_ +OSV]V%5Q+::N&4+)A^ MST\X&:EDIW,=+)3N!SA+C&]R!,;@C< M A$I1(.$\6.KXM$Y3-^ _ M>>:WN]Q:)RF;\!^\\UG8;M-/'*6'?]GJX9M, 6I6P M M &X\FF_'_N_.;W9:)R:;\?^[\YO=A5<2VFKAE"R8?L] M/'.5VRMV5.RN66"S%JVL6]RO:6*-P,M+)3N8Z62G<#G&]R<8WN0)C<$;@ M $(E*)!PGBQU;F2>+'5N!BKXJ]:Q7Q5ZP5KNZ52]Q6[NZ52]Q!2O<6BXM$Y3-^!_>>:SL-VFGCE+#O^SU<,VF +4K8 M M #<>33?C_P!WYS>K#1>33?C_ -WYS>K"JXEM-7#* M%DP_9Z>.+'5N!BKXJ]:Q7Q5ZP5KNZ52]Q6[NY4O<04 MKW%HG*9OP'[SS6]WN+1.4S?@/WGFL[#=IIXY2P[_ +/5PS:8 M2M@ M M -QY--^/_=^K"JX MEM-7#*%DP_9Z>.*G=! M2O<6BAH?*;OP'[SS6=ANTT\KAFTP!:E; M M ;CR:;\?^[\YO=EHO)GOQ_[OSV]655Q+ M::N&4+)A^ST\ MY F-P1N 0B4HD'">+'4RSQ8Z@8:F"XL5,%8*MW=*I=7+D*EV-X*5[B MT/E._P P_>>:WZ]Q:%RG_P"8?O/-9V&[33QREAW_ &>KAFTH!:E; M M ;ER9?C8_\ =^_\ >^:SL-VFGCE+#O\ L]7#-HX"U*V M M W3DOCV>WVS#1.2R-U"U:A@LQGML]##;AGH!DI9*7"E MDI!RA*(2"0 1*."9 <)<*F2=SA4#%4PUPSU0Q50"M7&]6N0MUPP7(! M1NT[W7_*O&K[W?O?,=BW*77O*W&K[V_O?,9V&[33QREAW_9ZN&;0@%J5L M M !O')3&N>[ M0T+DEC7.9? MNO/=A6J55Q+::N&4+)A^ST\\R[C:4V5O377 M.B._*6-?+.JTL9II\?\ ;IT;[/)Q3RN/\ 2M/S?_V;_65V MWN4^S2=@O&[SAHHW>>3^Y'^E*>P_]G&= JX_TG3V'_L:RNV]RGV.P7C=YPTH M;G.@E??*.P_]G'N&K[Y1V/VFLKMO<-.&X=P]SOC'8_:=Q%SOC'8 M_::RNV]RGV.P7C=YPT\;?W$5]\8['[3N)K[XQV/VFLKMO<-0&W] MQ-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RN MV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??& M.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV M.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[ MB:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C= MYPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^, M=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ; M?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK M*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U] M\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W* M?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[ M3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!> M-WG#4!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[ MXQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4 M!M_<37WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/V MFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<3 M7WQCL?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO M<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL M?M.XFOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XF MOOC'8_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO< M-0&W]Q-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8 M_::RNV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W] MQ-??&.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M.XFOOC'8_::RN MV]RGV.P7C=YPU ;?W$U]\8['[3N)K[XQV/VFLKMO<-0&W]Q-??& M.Q^T[B:^^,=C]IK*[;W*?8[!>-WG#4!M_<37WQCL?M(T(K[XQV/VFLKMO<-0&W]Q%??&.Q^U,:#U]\8['[365VWN4^QV"\;O.&GC<8T&N=\8['_ M -G*-!*Y_P!)1V'_ +&LKMO<-,&Z1H%7/\ I..P_P#9SCD_N3_I M2GL/_8UE=M[E/L=@O&[SAI WF.3RN?\ 2M/8?^SG3RC-60?=>UC(Q/W1L;K>SL[.UUS[[9[= M+07ZTIM;>JNB=,=V3=W.SJL[&*:O'_;E;I9Z(<**6:B&(R7.B&6F'"F&2F < MJ7.-SC$.4 Y$"8W (2B01P1.YR<9!PF/8<)AEF'"8!AJABJI6)AC MJ@%:JEBJI6JJ6.JD%.JAAJH7:J&.J@%*JVQ3;7IH<)M@HS;<9M+LVW'HP4NB M<9M=2]T74CHP4NB.B7>B1T?4"ET1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q M'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ M@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7> MCZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$ M=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J M!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z M/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1 MT7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H M%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH M^HZ/J!2Z+Q'1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q' M1>)=Z/J.CZ@4NB\1T7B7>CZCH^H%+HO$=%XEWH^HZ/J!2Z+Q'1>)=Z/J.CZ@ M4NB\1%I=Z/J.CZ@4^B.B7.CZD]$"E%I/1+G1IBWU J1;C.C6M@V 5>CZD]&L["=@%: M+:8MK&PF* 8(HKJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU M=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74 M#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X M;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R M;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFR MYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN> MKJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZ MC5U X;)LN>KJ-74#ALFRYZNHU=0.&R;+GJZC5U X;)LN>KJ-74#ALFRYZNHU M=0.&R;+GJZC5U X:C4YZNHU=0..J#5#EJ-0..KJ3J GRAPHIC 3 visual0002.jpg begin 644 visual0002.jpg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end